Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 2:34 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 1,836 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo- C Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

NCT00487825
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Canakinumab (investigational), Placebo, Methotrexate (MTX)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Nov 2, 2026, 2:34 AM EST
Active, not recruiting Phase 3 Interventional

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

NCT05360446
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Inclisiran sodium 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Huntsville, Alabama • Anchorage, Alaska • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 2, 2026, 2:34 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

NCT07152002
View directory record Official record
Conditions
Overweight or Obesity, Healthy
Interventions
LY4064912, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Los Alamitos, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 2, 2026, 2:34 AM EST
Terminated Phase 4 Interventional Results available

Armodafinil for Patients Starting Hepatitis C Virus Treatment

NCT01470651
View directory record Official record
Conditions
Hepatitis C
Interventions
Armodafinil, Sugar Pill
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Nov 2, 2026, 2:34 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

NCT07599670
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABBV-1758, Placebo for ABBV-1758
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 90 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
11
States / cities
Irvine, California • Boulder, Colorado • Bradenton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 2, 2026, 2:34 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

NCT00928083
View directory record Official record
Conditions
Malaria Falciparum, Malaria Vivax, Healthy Volunteers
Interventions
OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion, OZ439 800mg aqueous dispersion, OZ439 100mg API capsules, OZ439 400mg API capsules, OZ439 1600mg aqueous dispersion, OZ439 800mg API capsules, OZ439 1200mg API capsules, Placebo, OZ439 200mg aqueous dispersion
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Nov 2, 2026, 2:34 AM EST
Completed Phase 3 Interventional Results available

Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00121641
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Placebo matching Saxagliptin, Metformin, Placebo matching Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
83
States / cities
Anniston, Alabama • Birmingham, Alabama • Calera, Alabama + 80 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Nov 2, 2026, 2:34 AM EST
Completed Phase 2 Interventional Results available

ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19

NCT04988035
View directory record Official record
Conditions
COVID-19
Interventions
Danicopan, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Bakersfield, California • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Nov 2, 2026, 2:34 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Types of Resistant Starch and Their Effect on Appetite

NCT01125878
View directory record Official record
Conditions
Psychological Phenomena and Processes
Interventions
Placebo, Starch composite B, Starch composite C, Starch composite D
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Nov 2, 2026, 2:34 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

NCT02214433
View directory record Official record
Conditions
Bacterial Infections
Interventions
Placebo IV Solution, Debio 1450 IV Solution, Placebo Tablet or Capsule, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 Oral Solution, Pantoprazole
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Nov 2, 2026, 2:34 AM EST
Terminated Phase 2 Interventional Results available

Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C

NCT02971033
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
20mg ezetimibe, Placebo, 40mg ezetimibe
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Nov 2, 2026, 2:34 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124552
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001 Botulinum toxin type A (Dose A), RT001 Botulinum Toxin Type A (Dose B), Vehicle, Placebo
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Nov 2, 2026, 2:34 AM EST
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone

NCT04154033
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Dermatitis
Interventions
Naltrexone, Placebo Cream
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Nov 2, 2026, 2:34 AM EST
Completed Phase 3 Interventional Results available

The Plecanatide Irritable Bowel Syndrome With Constipation Safety and Efficacy Study (IBS-C)

NCT02387359
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
155
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 2, 2026, 2:34 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of CDD-2101 in Health Volunteers

NCT06570668
View directory record Official record
Conditions
Constipation - Functional
Interventions
CDD-2101
Drug
Lead sponsor
Centre for Chinese Herbal Medicine Drug Development Limited
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Nov 2, 2026, 2:34 AM EST
Completed Phase 2 Interventional

Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients

NCT00393120
View directory record Official record
Conditions
HIV Infections
Interventions
INCB009471, Placebo comparator
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Nov 2, 2026, 2:34 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Comparison of a Drug and Placebo in the Prevention of Migraine Headaches

NCT01122381
View directory record Official record
Conditions
Headache, Migraine
Interventions
ethosuximide, placebo comparator
Drug · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Nov 2, 2026, 2:34 AM EST
Completed Phase 3 Interventional

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

NCT03847428
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Bevacizumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
34
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 2, 2026, 2:34 AM EST
Suspended Phase 4 Interventional

Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy

NCT00591357
View directory record Official record
Conditions
Antibiotic-Associated Diarrhea, Clostridium Difficile
Interventions
loperamide, placebo
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Nov 2, 2026, 2:34 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02685020
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, Clade C gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 2, 2026, 2:34 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2484595 on Pharmacokinetics in Healthy Participants

NCT01448824
View directory record Official record
Conditions
Healthy Participants
Interventions
LY2484595, Placebo, Ketoconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Nov 2, 2026, 2:34 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

NCT06774313
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-142, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 2, 2026, 2:34 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

NCT03122223
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Nov 2, 2026, 2:34 AM EST
Completed Phase 2 Interventional Results available

Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

NCT03257995
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol maleate, Indacaterol acetate, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
North Dartmouth, Massachusetts • St Louis, Missouri • Skillman, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Nov 2, 2026, 2:34 AM EST